[HTML][HTML] SARS-CoV-2 variants, vaccines, and host immunity
P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …
Neurological manifestations of long-COVID syndrome: a narrative review
MI Stefanou, L Palaiodimou, E Bakola… - … advances in chronic …, 2022 - journals.sagepub.com
Accumulating evidence points toward a very high prevalence of prolonged neurological
symptoms among coronavirus disease 2019 (COVID-19) survivors. To date, there are no …
symptoms among coronavirus disease 2019 (COVID-19) survivors. To date, there are no …
Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study
D Ayoubkhani, C Bermingham, KB Pouwels… - bmj, 2022 - bmj.com
Objective To estimate associations between covid-19 vaccination and long covid symptoms
in adults with SARS-CoV-2 infection before vaccination. Design Observational cohort study …
in adults with SARS-CoV-2 infection before vaccination. Design Observational cohort study …
Effect of Covid-19 vaccination on transmission of alpha and delta variants
DW Eyre, D Taylor, M Purver, D Chapman… - … England Journal of …, 2022 - Mass Medical Soc
Background Before the emergence of the B. 1.617. 2 (delta) variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of …
respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
[HTML][HTML] Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …
[HTML][HTML] Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study
Objectives Highly effective vaccines against severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B …
2 (SARS-CoV-2) have been developed but variants of concerns are worrisome, especially B …
[HTML][HTML] Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom
We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2 …
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2 …
[HTML][HTML] Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re …